Cargando…
Polymer nanoparticle-assisted chemotherapy of pancreatic cancer
Pancreatic cancer is a lethal disease characterized by highly dense stroma fibrosis. Only 15–20% of patients with pancreatic cancer have resectable tumors, and only around 20% of them survive to 5 years. Traditional cancer treatments have little effect on their prognosis, and successful surgical res...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222269/ https://www.ncbi.nlm.nih.gov/pubmed/32426046 http://dx.doi.org/10.1177/1758835920915978 |
_version_ | 1783533536217661440 |
---|---|
author | Su, Tianqi Yang, Bo Gao, Tianren Liu, Tongjun Li, Jiannan |
author_facet | Su, Tianqi Yang, Bo Gao, Tianren Liu, Tongjun Li, Jiannan |
author_sort | Su, Tianqi |
collection | PubMed |
description | Pancreatic cancer is a lethal disease characterized by highly dense stroma fibrosis. Only 15–20% of patients with pancreatic cancer have resectable tumors, and only around 20% of them survive to 5 years. Traditional cancer treatments have little effect on their prognosis, and successful surgical resection combined with effective perioperative therapy is the main method for maximizing long-term survival. For this reason, chemotherapy is an adjunct treatment for resectable cancer and is the main therapy for incurable pancreatic cancer, including metastatic pancreatic adenocarcinoma. However, there are various side effects of chemotherapeutic medicine and low drug penetration because the complex tumor microenvironment limits the application of chemotherapy. As a novel strategy, polymer nanoparticles make it possible to target the tumor microenvironment, release cytotoxic agents through various responsive reactions, and thus overcome the treatment barrier. As drug carriers, polymer nanoparticles show marked advantages, such as increased drug delivery and efficiency, controlled drug release, decreased side effects, prolonged half-life, and evasion of immunogenic blockade. In this review, we discuss the factors that cause chemotherapy obstacles in pancreatic cancer, and introduce the application of polymer nanoparticles to treat pancreatic cancer. |
format | Online Article Text |
id | pubmed-7222269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-72222692020-05-18 Polymer nanoparticle-assisted chemotherapy of pancreatic cancer Su, Tianqi Yang, Bo Gao, Tianren Liu, Tongjun Li, Jiannan Ther Adv Med Oncol Review Pancreatic cancer is a lethal disease characterized by highly dense stroma fibrosis. Only 15–20% of patients with pancreatic cancer have resectable tumors, and only around 20% of them survive to 5 years. Traditional cancer treatments have little effect on their prognosis, and successful surgical resection combined with effective perioperative therapy is the main method for maximizing long-term survival. For this reason, chemotherapy is an adjunct treatment for resectable cancer and is the main therapy for incurable pancreatic cancer, including metastatic pancreatic adenocarcinoma. However, there are various side effects of chemotherapeutic medicine and low drug penetration because the complex tumor microenvironment limits the application of chemotherapy. As a novel strategy, polymer nanoparticles make it possible to target the tumor microenvironment, release cytotoxic agents through various responsive reactions, and thus overcome the treatment barrier. As drug carriers, polymer nanoparticles show marked advantages, such as increased drug delivery and efficiency, controlled drug release, decreased side effects, prolonged half-life, and evasion of immunogenic blockade. In this review, we discuss the factors that cause chemotherapy obstacles in pancreatic cancer, and introduce the application of polymer nanoparticles to treat pancreatic cancer. SAGE Publications 2020-05-08 /pmc/articles/PMC7222269/ /pubmed/32426046 http://dx.doi.org/10.1177/1758835920915978 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Su, Tianqi Yang, Bo Gao, Tianren Liu, Tongjun Li, Jiannan Polymer nanoparticle-assisted chemotherapy of pancreatic cancer |
title | Polymer nanoparticle-assisted chemotherapy of pancreatic cancer |
title_full | Polymer nanoparticle-assisted chemotherapy of pancreatic cancer |
title_fullStr | Polymer nanoparticle-assisted chemotherapy of pancreatic cancer |
title_full_unstemmed | Polymer nanoparticle-assisted chemotherapy of pancreatic cancer |
title_short | Polymer nanoparticle-assisted chemotherapy of pancreatic cancer |
title_sort | polymer nanoparticle-assisted chemotherapy of pancreatic cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222269/ https://www.ncbi.nlm.nih.gov/pubmed/32426046 http://dx.doi.org/10.1177/1758835920915978 |
work_keys_str_mv | AT sutianqi polymernanoparticleassistedchemotherapyofpancreaticcancer AT yangbo polymernanoparticleassistedchemotherapyofpancreaticcancer AT gaotianren polymernanoparticleassistedchemotherapyofpancreaticcancer AT liutongjun polymernanoparticleassistedchemotherapyofpancreaticcancer AT lijiannan polymernanoparticleassistedchemotherapyofpancreaticcancer |